How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
In addition to Philadelphia, the Democratic National Committee said it is also considering Denver and Boston on its narrowed short list of cities to hold the next presidential nominating convention. A ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.
Recursion Pharmaceuticals Inc insiders reported 6 transactions totaling $589,430.56. Activity included 2 tax payments, 2 stock sales, and 2 stock awards between July and August 2026. View more Major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results